These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33459189)

  • 21. Metabolic syndrome and smoking are associated with persistence of nocturia after transurethral resection of the prostate.
    De Nunzio C; Tema G; Lombardo R; Cicione A; Nacchia A; D'Annunzio S; Sarchi L; Proietti F; Brassetti A; Tubaro A
    Neurourol Urodyn; 2019 Aug; 38(6):1692-1699. PubMed ID: 31107572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia.
    Fowler C; McAllister W; Plail R; Karim O; Yang Q
    Health Technol Assess; 2005 Feb; 9(4):iii-iv, 1-30. PubMed ID: 15698525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usage of GreenLight HPS 180-W laser vaporisation for treatment of benign prostatic hyperplasia.
    Jovanović M; Džamić Z; Aćimović M; Kajmaković B; Pejčić T
    Acta Chir Iugosl; 2014; 61(1):57-61. PubMed ID: 25782227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Hwang EC; Jung JH; Borofsky M; Kim MH; Dahm P
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD013143. PubMed ID: 30759311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of monopolar TURP, bipolar TURP and photoselective vaporization of prostate for enlarged prostate on erectile function.
    Vasudeva P; Kumar N; Kumar A; Kumar G; Patel M; Gupta P
    Low Urin Tract Symptoms; 2019 Jan; 11(1):24-29. PubMed ID: 28762663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benign prostatic hyperplasia: mode of presentation and postoperative outcome.
    Khan M; Khan AL; Khan S; Nawaz H
    J Pak Med Assoc; 2005 Jan; 55(1):20-3. PubMed ID: 15816691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis.
    Davis NF; Jack GS; Witjes WP; Bjartell A; Caris C; Patel A; de la Taille A; Lawrentschuk N; Bolton DM; Tubaro A
    World J Urol; 2019 May; 37(5):873-878. PubMed ID: 30145778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lower Urinary Tract Symptoms Following Transurethral Resection of Prostate.
    Kim SJ; Al Hussein Alawamlh O; Chughtai B; Lee RK
    Curr Urol Rep; 2018 Aug; 19(10):85. PubMed ID: 30128964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A matched-pair analysis of patients with medium-sized prostates (50 cc) treated for male LUTS with HoLEP or TURP.
    Magistro G; Westhofen T; Stief CG; Weinhold P
    Low Urin Tract Symptoms; 2020 May; 12(2):117-122. PubMed ID: 31573756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bipolar transurethral vaporization: a superior procedure in benign prostatic hyperplasia: a prospective randomized comparison with bipolar TURP.
    Falahatkar S; Mokhtari G; Moghaddam KG; Asadollahzade A; Farzan A; Shahab E; Ghasemi A; Allahkhah A; Esmaeili S
    Int Braz J Urol; 2014; 40(3):346-55. PubMed ID: 25010300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Quality of life in patients with lower urinary tract symptoms after TURP for benign prostatic hyperplasia].
    Pushkar DY; Bernikov AN; Khodyreva LA; Dudareva AA; Al'-Shukri SK; Amdii RE; Aboyan IA; Shiranov KA; Medvedev VL; Efremov ME
    Urologiia; 2018 Mar; (1):53-61. PubMed ID: 29634135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective randomized study comparing monopolar with bipolar transurethral resection of prostate in benign prostatic obstruction: 36-month outcomes.
    Al-Rawashdah SF; Pastore AL; Salhi YA; Fuschi A; Petrozza V; Maurizi A; Illiano E; Costantini E; Palleschi G; Carbone A
    World J Urol; 2017 Oct; 35(10):1595-1601. PubMed ID: 28243790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interventional therapies for lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
    Seitz M; Bader M; Tilki D; Stief C; Gratzke C
    Minerva Urol Nefrol; 2012 Jun; 64(2):123-33. PubMed ID: 22617306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic Value of the Transurethral Resection in Saline System for Treatment of Benign Prostatic Hyperplasia in England and Wales: Systematic Review, Meta-analysis, and Cost-Consequence Model.
    Treharne C; Crowe L; Booth D; Ihara Z
    Eur Urol Focus; 2018 Mar; 4(2):270-279. PubMed ID: 28753756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified transurethral resection of the prostate for the management of BPH-related refractory lower urinary tract symptoms in patients with a history of pelvic fracture urethral injury reconstruction.
    Mishra K; Baeza C; Bukavina L; Gómez RG
    Int Urol Nephrol; 2019 Dec; 51(12):2137-2141. PubMed ID: 31493103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reoperation After Holmium Laser Enucleation of the Prostate for Management of Benign Prostatic Hyperplasia: Assessment of Risk Factors with Time to Event Analysis.
    Elkoushy MA; Elshal AM; Elhilali MM
    J Endourol; 2015 Jul; 29(7):797-804. PubMed ID: 25705817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update.
    Cornu JN; Ahyai S; Bachmann A; de la Rosette J; Gilling P; Gratzke C; McVary K; Novara G; Woo H; Madersbacher S
    Eur Urol; 2015 Jun; 67(6):1066-1096. PubMed ID: 24972732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.
    Oelke M; Bachmann A; Descazeaud A; Emberton M; Gravas S; Michel MC; N'dow J; Nordling J; de la Rosette JJ;
    Eur Urol; 2013 Jul; 64(1):118-40. PubMed ID: 23541338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up.
    Porpiglia F; Fiori C; Bertolo R; Garrou D; Cattaneo G; Amparore D
    BJU Int; 2015 Aug; 116(2):278-87. PubMed ID: 25382816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.